CNNMoney.com – A major shareholder of Amylin Pharmaceuticals Inc. ( AMLN) is backing a slate of dissident directors nominated by Carl Icahn and another hedge-fund manager, Eastbourne Capital Management.

P. Schoenfeld and Associates, which owned 2.1 million Amylin shares as of the end of the first quarter, told Dow Jones Newswires Thursday it supports all five of Icahn’s and Eastbourne’s nominees because it sees that as the only opportunity for the company to make significant strides.

"We would like to see the largest minority possible elected to the Amylin board," said P. Schoenfeld founder Peter Schoenfeld.

Read Complete Article

Tags: 1-million, amln, amylin pharmaceuticals inc, capital-management, carl-icahn, dow jones newswires, dow-jones, first quarter, hedge-fund-manager, schoenfeld, shareholder, slate, strides